In VivoA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic
Pink SheetA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic
Pink SheetThe US Food and Drug Administration closed out last week with the approvals of two novel agents for rare diseases, Travere Therapeutics, Inc. 's Filspari for IgA nephropathy and Chiesi Global Rare Di
Pink SheetThe turbulent year of 2022 ended a remarkable run of record high novel approval counts from the US FDA with a 25% plunge from 2021, but from a longer perspective the 45 new molecular entities and nove